-
Mashup Score: 0Loin Pain in Patients With IgAN | Docwire News - 3 hour(s) ago
A study examined the impact loin pain has on IgA nephropathy (IgAN) patients’ quality of life and strategies to manage the pain.
Source: www.docwirenews.comCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 0
The European label for Ozempic will be updated to include an indication for risk reduction for events related to kidney disease.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
European Medicines Agency clears the way for Ozempic's label to list a kidney disease indication. https://t.co/92Dea1RT7P #ozempic #kidneydisease #nephtwitter https://t.co/ZtISh8nplE
-
-
Mashup Score: 1Post-AKI Mortality, Readmission With Blood Pressure, Time From Discharge | Docwire News - 11 hour(s) ago
A study examined the associations of systolic blood pressure with mortality and hospital readmission post-acute kidney injury (AKI).
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
New research addressed the lack of data on the association of blood pressure with post-AKI outcomes and the degree to which time from discharge is associated with risks and benefits. #acutekidneyinjury #AKI #bloodpressure #nephtwitter https://t.co/QhALOkXTSK https://t.co/fR8SVJgdaC
-
-
Mashup Score: 0EMPA-KIDNEY Post-Trial Findings | Docwire News - 1 day(s) ago
In post-trial follow-up of EMPA-KIDNEY, benefits of empagliflozin continued for a period after discontinuation but were lesser and seemed temporary.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
Post-trial follow-up of EMPA-KIDNEY gave a more complete measurement of the total effects of 2 years of #empagliflozin in #CKD. #kidneywk #kidneydisease #nephrology #nephtwitter https://t.co/3GsI86mwaT https://t.co/7ZXLPdrVMx
-
-
Mashup Score: 0
A study examined the association between circulating inflammatory proteins and disease progression in IgA nephropathy (IgAN).
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
Research presented at #KidneyWk examined the association between circulating inflammatory proteins and disease progression in #IgAN. #nephrology #iganephropathy #nephtwitter https://t.co/4r3kqlFJdD https://t.co/RsvCJ8tPzQ
-
-
Mashup Score: 2Treatment for Primary Membranous Nephropathy: Feasibility Study Results | Docwire News - 2 day(s) ago
Bruton tyrosine kinase inhibitor zanubrutinib was found to be well tolerated and showed activity in patients with primary membranous nephropathy.
Source: www.docwirenews.comCategories: General Medicine News, NephrologyTweet-
The study assessed the efficacy and safety of BTK inhibitor #zanubrutinib in patients with primary membranous nephropathy. #kidneywk #nephrology #glomerulardisease #nephtwitter https://t.co/wMKy4FuZhu https://t.co/xATUtmTgLs
-
-
Mashup Score: 0
Semaglutide reduced the risk of death, including cardiovascular death, among patients in the FLOW trial, who had chronic kidney disease (CKD) and type 2 diabetes.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
A subanalysis of FLOW data examined the effect of #semaglutide on mortality in patients with type 2 #diabetes and #CKD. #kidneywk #kidneydisease #nephrology #nephtwitter https://t.co/gHmHGUYJVw https://t.co/0mukFBncYx
-
-
Mashup Score: 4
The US Food and Drug Administration (FDA) has approved durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC).
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📰 REGUALTORY UPDATE: The US Food and Drug Administration has approved durvalumab for adults with LS-SCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ➡️ Learn more: https://t.co/xv5SVGZG9j #SCLC #LCSM https://t.co/dj7fwVAB2F
-
-
Mashup Score: 2Can Trilaciclib Help Prevent Hematological Adverse Events With Chemotherapy in Patients With SCLC? | Docwire News - 3 day(s) ago
Trilaciclib, a drug approved for patients with extensive-stage small cell lung cancer, has “consistently demonstrated efficacy” in reducing chemotherapy-induced myelosuppresion.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 Trilaciclib, a drug approved for patients with extensive-stage SCLC, “consistently demonstrated efficacy” in reducing chemotherapy-induced myelosuppression, according to research by a team from @BeaumontHealth. ➡️ Read more: https://t.co/Ssea2jSMv4 https://t.co/QUoUekmRAn
-
-
Mashup Score: 0Case Report: Patient With Hyponatremia and Fontan-Associated Cardiac Cirrhosis | Docwire News - 3 day(s) ago
Contrary to recommendations, low-dose tolvaptan may be an option for refractory hyponatremia in cirrhosis.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
Researchers determined that #tolvaptan should be considered as an alternative therapy for refractory #hyponatremia in cirrhosis. #kidneywk #nephtwitter https://t.co/k9PyiMmEEg https://t.co/5jdlOtjW9t
-
Loin pain is common among patients with IgAN but little is reported about its impact on quality of life or management strategies. #kidneywk #iganephropathy #loinpain #nephtwitter https://t.co/XsXjQX8OQF https://t.co/Jx6tMflGaK